NCT05361655
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy)

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received Ibrance/palbociclib + AI or AI as first-line therapy
Exclusions: Patients with prior treatment of a non-steroidal aromatase inhibitor (AI) (e.g. Arimidex/anastrozole, Aromasin/exemestane, Femara/letrozole), a SERD (e.g. Faslodex/fulvestrant, Zoladex, Lupron), or tamoxifen, raloxifene, toremifene in combination with a CDK 4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib) for metastatic breast cancer (MBC)
https://ClinicalTrials.gov/show/NCT05361655